Canaural eyrnadropar, dreifa
Canaural eyrnadropar, dreifa
Authorised
- Diethanolamine fusidate
- Framycetin sulfate
- Nystatin
- Prednisolone
Product identification
Medicine name:
Canaural eyrnadropar, dreifa
Active substance:
- Diethanolamine fusidate
- Framycetin sulfate
- Nystatin
- Prednisolone
Target species:
-
Dog
Route of administration:
-
Auricular use
Product details
Active substance and strength:
-
Diethanolamine fusidate5.00milligram(s)1.00gram(s)
-
Framycetin sulfate5.00milligram(s)1.00gram(s)
-
Nystatin100000.00international unit(s)1.00gram(s)
-
Prednisolone2.50milligram(s)1.00gram(s)
Pharmaceutical form:
-
Ear drops, suspension
Withdrawal period by route of administration:
-
Auricular use
- Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QS02CA01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Iceland
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
- Dechra Veterinary Products A/S
Marketing authorisation date:
Manufacturing sites for batch release:
- Genera Istrazivanja d.o.o.
- Dales Pharmaceuticals Limited
Responsible authority:
- Icelandic Medicines Agency
Authorisation number:
- 822774
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it in another language below.
Icelandic (PDF)
Published on: 1/03/2022
Package Leaflet
This document does not exist in this language (English). You can find it in another language below.
Icelandic (PDF)
Published on: 1/03/2022
How useful was this page?: